Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment
Purpose Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. Methods Patients with advanced solid mal...
Gespeichert in:
Veröffentlicht in: | Cancer chemotherapy and pharmacology 2017-07, Vol.80 (1), p.29-36 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study.
Methods
Patients with advanced solid malignancies and hepatic impairment were enrolled into one of four cohorts: normal [bilirubin (bili) |
---|---|
ISSN: | 0344-5704 1432-0843 |
DOI: | 10.1007/s00280-017-3315-8 |